- UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
- UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
- UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
- UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
- UroGen Pharma Appoints David Lin as New Chief Commercial Officer
- UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
- UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
- UroGen Pharma to Participate at Upcoming Investor Conferences
- New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
More ▼
Key statistics
On Wednesday, Urogen Pharma Ltd (URGN:NMQ) closed at 15.01, 72.73% above the 52 week low of 8.69 set on Jul 26, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.18 |
---|---|
High | 15.86 |
Low | 14.89 |
Bid | 14.75 |
Offer | 15.20 |
Previous close | 15.14 |
Average volume | 800.90k |
---|---|
Shares outstanding | 41.13m |
Free float | 37.17m |
P/E (TTM) | -- |
Market cap | 622.67m USD |
EPS (TTM) | -3.39 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼